{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:34:39Z","timestamp":1791855279522,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtct.2025.11.028","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:34:09Z","timestamp":1763703249000},"page":"470.e1-470.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Conditioning for Transplantation in Inborn Errors of Immunity"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7793-669X","authenticated-orcid":false,"given":"Thomas","family":"Pfeiffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1425-1623","authenticated-orcid":false,"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5452-9530","authenticated-orcid":false,"given":"Melissa","family":"Mavers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-1139","authenticated-orcid":false,"given":"Robert J.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-7938","authenticated-orcid":false,"given":"Troy C.","family":"Quigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Eckrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3018-1144","authenticated-orcid":false,"given":"Lisa M.","family":"Madden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Lipsitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6902-0876","authenticated-orcid":false,"given":"Jeffrey J.","family":"Bednarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jtct.2025.11.028_bib0001","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jtct.2025.11.028_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1279201","article-title":"Too much of a good thing: a review of primary immune regulatory disorders","volume":"14","author":"Tsilifis","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.028_bib0003","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41576-023-00656-z","article-title":"Inborn errors of immunity: an expanding universe of disease and genetic architecture","volume":"25","author":"Akalu","year":"2024","journal-title":"Nat Rev Genet"},{"issue":"9","key":"10.1016\/j.jtct.2025.11.028_bib0004","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.jtct.2025.11.028_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1162605","article-title":"Personalized hematopoietic stem cell transplantation for inborn errors of immunity","volume":"14","author":"Slatter","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.028_bib0006","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.bmt.1704795","article-title":"A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders","volume":"35","author":"Shenoy","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 2","key":"10.1016\/j.jtct.2025.11.028_bib0007","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1038\/bmt.2008.283","article-title":"The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis","volume":"42","author":"Cooper","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"10.1016\/j.jtct.2025.11.028_bib0008","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1182\/blood-2010-04-282392","article-title":"Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation","volume":"116","author":"Marsh","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.028_bib0009","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2025.11.028_bib0010","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2010-05-286856","article-title":"Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution","volume":"116","author":"Chakraverty","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.11.028_bib0011","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.bbmt.2013.09.001","article-title":"An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis","volume":"19","author":"Marsh","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.028_bib0012","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","article-title":"Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT","volume":"127","author":"Marsh","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.11.028_bib0013","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/bjh.16370","article-title":"Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH","volume":"188","author":"Naik","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.028_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28030","article-title":"A single-center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease","volume":"67","author":"Bhatt","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2025.11.028_bib0015","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00467-015-3102-x","article-title":"Renal involvement in the immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) disorder","volume":"30","author":"Sheikine","year":"2015","journal-title":"Pediatric Nephrology"},{"issue":"13","key":"10.1016\/j.jtct.2025.11.028_bib0016","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2018-01-828277","article-title":"Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies","volume":"132","author":"Allen","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.11.028_bib0017","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2004-03-0960","article-title":"Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen","volume":"105","author":"Rao","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.11.028_bib0018","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.bbmt.2015.04.009","volume":"21","author":"Marsh","year":"2015","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.028_bib0019","doi-asserted-by":"crossref","first-page":"101.e1","DOI":"10.1016\/j.jtct.2023.09.024","article-title":"Age impacts risk of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for non-severe combined immune deficiency inborn errors of immunity","volume":"30","author":"Fitch","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.11.028_bib0020","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtct.2025.02.002","article-title":"Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioning","volume":"31","author":"Dvorak","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2025.11.028_bib0021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1365-2141.1999.01477.x","article-title":"Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children","volume":"106","author":"Marley","year":"1999","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.028_bib0022","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ijlh.12073","article-title":"Bone marrow evaluation for pediatric patients","volume":"35","author":"Proytcheva","year":"2013","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.11.028_bib0023","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.178.3.787","article-title":"Ontogeny-related changes in proliferative potential of human hematopoietic cells","volume":"178","author":"Lansdorp","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtct.2025.11.028_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211013985","article-title":"Treosulfan-based conditioning for inborn errors of immunity","volume":"12","author":"Slatter","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"22","key":"10.1016\/j.jtct.2025.11.028_bib0025","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1182\/bloodadvances.2021005231","article-title":"Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure","volume":"5","author":"Sabulski","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.jtct.2025.11.028_bib0026","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/bloodadvances.2022009051","article-title":"Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study","volume":"7","author":"Achini-Gutzwiller","year":"2023","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725016033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725016033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:32:16Z","timestamp":1778355136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725016033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666636725016033"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.028","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Conditioning for Transplantation in Inborn Errors of Immunity","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}